Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 76


Ustekinumab for the treatment of refractory giant cell arteritis.

Conway R, O'Neill L, O'Flynn E, Gallagher P, McCarthy GM, Murphy CC, Veale DJ, Fearon U, Molloy ES.

Ann Rheum Dis. 2016 May 3. pii: annrheumdis-2016-209351. doi: 10.1136/annrheumdis-2016-209351. [Epub ahead of print] No abstract available.


Dysregulated bioenergetics: a key regulator of joint inflammation.

Biniecka M, Canavan M, McGarry T, Gao W, McCormick J, Cregan S, Gallagher L, Smith T, Phelan JJ, Ryan J, O'Sullivan J, Ng CT, Veale DJ, Fearon U.

Ann Rheum Dis. 2016 Mar 24. pii: annrheumdis-2015-208476. doi: 10.1136/annrheumdis-2015-208476. [Epub ahead of print]


What makes psoriatic and rheumatoid arthritis so different?

Veale DJ, Fearon U.

RMD Open. 2015 Apr 28;1(1):e000025. doi: 10.1136/rmdopen-2014-000025. eCollection 2015. Review.


Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.

Gao W, McGarry T, Orr C, McCormick J, Veale DJ, Fearon U.

Ann Rheum Dis. 2016 Jan;75(1):311-5. doi: 10.1136/annrheumdis-2014-207201. Epub 2015 Sep 9.


C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis.

Muthana M, Hawtree S, Wilshaw A, Linehan E, Roberts H, Khetan S, Adeleke G, Wright F, Akil M, Fearon U, Veale D, Ciani B, Wilson AG.

Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11618-23. doi: 10.1073/pnas.1501947112. Epub 2015 Aug 27.


Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms.

Connolly M, Rooney PR, McGarry T, Maratha AX, McCormick J, Miggin SM, Veale DJ, Fearon U.

Ann Rheum Dis. 2015 Aug 19. pii: annrheumdis-2015-207655. doi: 10.1136/annrheumdis-2015-207655. [Epub ahead of print]


Key Challenges in Rheumatic and Musculoskeletal Disease Translational Research.

Fearon U, Veale DJ.

EBioMedicine. 2014 Nov 18;1(2-3):95-6. doi: 10.1016/j.ebiom.2014.11.011. eCollection 2014 Dec. No abstract available.


A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-α treatment of psoriatic arthritis.

Collins ES, Butt AQ, Gibson DS, Dunn MJ, Fearon U, van Kuijk AW, Gerlag DM, Pontifex E, Veale DJ, Tak PP, FitzGerald O, Pennington SR.

Proteomics Clin Appl. 2015 Jun 24. doi: 10.1002/prca.201500051. [Epub ahead of print]


Polyfunctional, Pathogenic CD161+ Th17 Lineage Cells Are Resistant to Regulatory T Cell-Mediated Suppression in the Context of Autoimmunity.

Basdeo SA, Moran B, Cluxton D, Canavan M, McCormick J, Connolly M, Orr C, Mills KH, Veale DJ, Fearon U, Fletcher JM.

J Immunol. 2015 Jul 15;195(2):528-40. doi: 10.4049/jimmunol.1402990. Epub 2015 Jun 10.


Toll-like receptor 2 (TLR2) induces migration and invasive mechanisms in rheumatoid arthritis.

McGarry T, Veale DJ, Gao W, Orr C, Fearon U, Connolly M.

Arthritis Res Ther. 2015 Jun 9;17:153. doi: 10.1186/s13075-015-0664-8.


Regulation of Inflammation and Angiogenesis in Giant Cell Arteritis by Acute-Phase Serum Amyloid A.

O'Neill L, Rooney P, Molloy D, Connolly M, McCormick J, McCarthy G, Veale DJ, Murphy CC, Fearon U, Molloy E.

Arthritis Rheumatol. 2015 Sep;67(9):2447-56. doi: 10.1002/art.39217.


Biomarkers for rheumatoid and psoriatic arthritis.

Verheul MK, Fearon U, Trouw LA, Veale DJ.

Clin Immunol. 2015 Nov;161(1):2-10. doi: 10.1016/j.clim.2015.04.005. Epub 2015 Apr 28. Review.


Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis.

Ademowo OS, Hernandez B, Collins E, Rooney C, Fearon U, van Kuijk AW, Tak PP, Gerlag DM, FitzGerald O, Pennington SR.

Ann Rheum Dis. 2016 Jan;75(1):234-41. doi: 10.1136/annrheumdis-2014-205417. Epub 2014 Sep 3.


Redox-mediated angiogenesis in the hypoxic joint of inflammatory arthritis.

Biniecka M, Connolly M, Gao W, Ng CT, Balogh E, Gogarty M, Santos L, Murphy E, Brayden D, Veale DJ, Fearon U.

Arthritis Rheumatol. 2014 Dec;66(12):3300-10. doi: 10.1002/art.38822.


Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis.

Gao W, McCormick J, Connolly M, Balogh E, Veale DJ, Fearon U.

Ann Rheum Dis. 2015 Jun;74(6):1275-83. doi: 10.1136/annrheumdis-2013-204105. Epub 2014 Feb 13.


Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder.

Balogh E, Madruga Dias J, Orr C, Mullan R, Harty L, FitzGerald O, Gallagher P, Molloy M, O'Flynn E, Kelly A, Minnock P, O'Neill M, Moore L, Murray M, Fearon U, Veale DJ.

Arthritis Res Ther. 2013 Dec 24;15(6):R221. doi: 10.1186/ar4421.


Notch-1 mediates endothelial cell activation and invasion in psoriasis.

Rooney P, Connolly M, Gao W, McCormick J, Biniecka M, Sullivan O, Kirby B, Sweeney C, Molloy E, Markham T, Fearon U, Veale DJ.

Exp Dermatol. 2014 Feb;23(2):113-8. doi: 10.1111/exd.12306.


Hypoxia: how does the monocyte-macrophage system respond to changes in oxygen availability?

Strehl C, Fangradt M, Fearon U, Gaber T, Buttgereit F, Veale DJ.

J Leukoc Biol. 2014 Feb;95(2):233-41. doi: 10.1189/jlb.1212627. Epub 2013 Oct 29. Review.


Tumor necrosis factor inhibition modulates thrombospondin-1 expression in human inflammatory joint disease through altered NR4A2 activity.

McMorrow JP, Crean D, Gogarty M, Smyth A, Connolly M, Cummins E, Veale D, Fearon U, Tak PP, Fitzgerald O, Murphy EP.

Am J Pathol. 2013 Oct;183(4):1243-57. doi: 10.1016/j.ajpath.2013.06.029. Epub 2013 Aug 6.


Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2.

Gao W, Sweeney C, Walsh C, Rooney P, McCormick J, Veale DJ, Fearon U.

Ann Rheum Dis. 2013 Jun;72(6):1080-8. doi: 10.1136/annrheumdis-2012-201978. Epub 2012 Nov 17.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk